Share

February 09, 2016; 86 (6) Article

Periventricular hyperintensities are associated with elevated cerebral amyloid

Michael Marnane, Osama O. Al-Jawadi, Shervin Mortazavi, Kathleen J. Pogorzelec, Bing Wei Wang, Howard H. Feldman, Ging-Yuek R. Hsiung, For the Alzheimer's Disease Neuroimaging Initiative
First published January 8, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002352
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
391

Share

Article Information

vol. 86 no. 6 535-543
DOI: 
https://doi.org/10.1212/WNL.0000000000002352
PubMed: 
26747881
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 1, 2015
  • Accepted in final form October 19, 2015
  • First Published January 8, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Michael Marnane, MD, PhD,
    2. Osama O. Al-Jawadi,
    3. Shervin Mortazavi,
    4. Kathleen J. Pogorzelec, BSc,
    5. Bing Wei Wang, MD,
    6. Howard H. Feldman, MD,
    7. Ging-Yuek R. Hsiung, MD, MHSc;
    8. For the Alzheimer's Disease Neuroimaging Initiative
  1. Michael Marnane, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) American Academy of Neurology fellow travel award (2) Alzheimer Association International Conference fellow travel award

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Heart and Stroke Foundation of Canada (fellowship salary award)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Osama O. Al-Jawadi,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Shervin Mortazavi,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Kathleen J. Pogorzelec, BSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Bing Wei Wang, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Howard H. Feldman, MD,
    7. Scientific Advisory Boards:

    1. 1. Commercial; Eli Lilly and Co: SAB 2. Commercial; Biogen Idec: SAB 3. Commercial Genentech: DMC 4. Commercial Eisai LTD: DSMB 5. Commercial ISIS Pharmaceuticals: Advisory Board 6. Commercial Arena Pharmaceuticals: Advisory Board Payments from Commercial Organizations to UBC 6. Not for Profit: Tau Consortium: SAB honoraria

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Not for Profit: Tau Consortium Investigator Meetings 2015 2. Not for Profit: New York Academy of Sciences and US Against Alzheimer's Disease 2013 and 2014 (travel expenses) 3. Not for Profit: Alzheimer Society of Canada 2015 (travel expenses) 4. Not for Profit: US Alzheimer Association 2015 4. Not for Profit: Brain Canada 2014 (travel expenses)

    Editorial Boards:

    1. NONE

    Patents:

    1. US Serial Number PCT/2007/070008 Detecting and Treating Dementia

    Publishing Royalties:

    1. Royalties from the book Atlas of Alzheimer?s Disease (2007) Informa Health London

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Commercial Arena Pharmaceuticals LTD: 2014

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. Canadian Institutes of Health Research CIHR # 287674 (2013-18)role co Principal Investigator, 2. CIHR Consortium for Neurodegeneration and Aging co Principal Investigator (2014-19), 3. CIHR Canadian Pipeline for AD Therapeutics 2015 Principal Investigator (2015-16)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Ging-Yuek R. Hsiung, MD, MHSc;
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Hsiung has received research support as a clinical trials site investigator from Eli Lilly, Hoffman-La Roche, and TauRx, and has received honorarium for participation in expert review committee with Merck and Eli Lilly.

    Research Support, Government Entities:

    1. Dr. Hsiung has provided investigator's report to the British Columbia Ministry of Health on the Alzheimer Disease Therapeutic Initiative.

    Research Support, Academic Entities:

    1. Dr. Hsiung is supported by a Clinical Genetics Investigatorship award from the CIHR, and has received research funding from the CIHR, Alzheimer Society of Canada, and NIH.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. For the Alzheimer's Disease Neuroimaging Initiative
    1. From the Clinic for Alzheimer Disease and Related Disorders, Djavad Mowafaghian Center for Brain Health (M.M., O.O.A.-J., S.M., K.J.P., B.W.W., H.H.F., G.-Y.R.H.), and Department of Medicine, Division of Neurology (M.M., H.H.F., G.-Y.R.H.), University of British Columbia, Vancouver, Canada.
    1. Correspondence to Dr. Marnane: michael.marnane{at}vch.ca
    View Full Text

    Article usage

    Article usage: January 2016 to April 2023

    AbstractFullPdfSource
    Jan 2016556043Highwire
    Feb 201616253690Highwire
    Mar 2016267147Highwire
    Apr 2016127910Highwire
    May 20169436Highwire
    Jun 20166852Highwire
    Jul 20169934Highwire
    Aug 20169623Highwire
    Sep 20166802Highwire
    Oct 20166804Highwire
    Nov 20166111Highwire
    Dec 20165444Highwire
    Jan 20176113Highwire
    Feb 20174322Highwire
    Feb 20170810pmc
    Mar 20173920Highwire
    Mar 20170118pmc
    Apr 20173912Highwire
    Apr 2017466pmc
    May 20174600Highwire
    May 2017182322pmc
    Jun 20173801Highwire
    Jun 2017233pmc
    Jul 20172611Highwire
    Jul 2017356pmc
    Aug 20172812Highwire
    Aug 201741313pmc
    Sep 20171701Highwire
    Sep 2017233pmc
    Oct 20172401Highwire
    Oct 201713129pmc
    Nov 20174212Highwire
    Nov 20174118pmc
    Dec 20172111Highwire
    Jan 20182822Highwire
    Feb 20182542Highwire
    Mar 20181823Highwire
    Apr 20182101Highwire
    Apr 201871716pmc
    May 20182301Highwire
    Jun 20182800Highwire
    Jun 201811920pmc
    Jul 20183112Highwire
    Aug 20181612Highwire
    Aug 201831212pmc
    Sep 20183924Highwire
    Oct 20182623Highwire
    Nov 20183412Highwire
    Dec 20183013Highwire
    Jan 20191702Highwire
    Feb 20191511Highwire
    Mar 20193401Highwire
    Apr 20192010Highwire
    May 20192622Highwire
    Jun 20191900Highwire
    Jul 20191312Highwire
    Aug 20191312Highwire
    Sep 20191621Highwire
    Oct 20191210Highwire
    Nov 20191900Highwire
    Dec 2019920Highwire
    Jan 20202400Highwire
    Feb 20201631Highwire
    Mar 20201160Highwire
    Apr 20202220Highwire
    May 20201620Highwire
    Jun 20203752Highwire
    Jul 20202500Highwire
    Aug 20201621Highwire
    Sep 20202900Highwire
    Oct 20203110Highwire
    Nov 20203820Highwire
    Dec 20202300Highwire
    Jan 20213710Highwire
    Feb 20213400Highwire
    Mar 20211821Highwire
    Apr 20213533Highwire
    May 20213622Highwire
    Jun 20213010Highwire
    Jul 20215410Highwire
    Aug 20212700Highwire
    Sep 20212010Highwire
    Oct 20212641Highwire
    Nov 20214941Highwire
    Dec 20215200Highwire
    Jan 20223212Highwire
    Feb 20223811Highwire
    Mar 20223612Highwire
    Apr 20223201Highwire
    May 20224831Highwire
    Jun 20224100Highwire
    Jul 20223543Highwire
    Aug 20223020Highwire
    Sep 20223810Highwire
    Oct 20223052Highwire
    Nov 20223310Highwire
    Dec 20223500Highwire
    Jan 20234820Highwire
    Feb 20234810Highwire
    Mar 20234200Highwire
    Apr 20233443Highwire

    Cited By...

    Letters: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Topics Discussed

    Alert Me

    Recommended articles